CytoDyn (STU:296) Total Liabilities: €103.88 Mil (As of Feb. 2026)


STU:296 CytoDyn Inc STU:296
28 GF Score
Price €0.20
! 1 Warning Sign
View Full Analysis

What is CytoDyn Total Liabilities?

CytoDyn STU:296 +3.13% 28 Total Liabilities is €103.88 Mil as of Feb. 2026. GuruFocus rates STU:296 with a GF Score™ of 28/100. The stock has 1 warning sign investors should review.

CytoDyn's Total Liabilities for the quarter that ended in Feb. 2026 was €103.88 Mil.

CytoDyn's quarterly Total Liabilities increased from Aug. 2025 (€97.06 Mil) to Nov. 2025 (€111.31 Mil) but then declined from Nov. 2025 (€111.31 Mil) to Feb. 2026 (€103.88 Mil).

CytoDyn's annual Total Liabilities increased from May. 2023 (€111.13 Mil) to May. 2024 (€118.30 Mil) but then declined from May. 2024 (€118.30 Mil) to May. 2025 (€101.20 Mil).

CytoDyn Total Liabilities Historical Data

* Premium members only.

The historical data trend for CytoDyn's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CytoDyn Total Liabilities Chart

CytoDyn Annual Data
Trend May16 May17 May18 May19 May20 May21 May22 May23 May24 May25
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 126.00 116.91 111.13 118.30 101.20

CytoDyn Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 109.60 101.20 97.06 111.31 103.88
STU:296
28GF Score
CytoDyn Inc STU:296
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CytoDyn Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

CytoDyn's Total Liabilities for the fiscal year that ended in May. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=62.549+(0+38.648
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=101.20

Total Liabilities=Total Assets (A: May. 2025 )-Total Equity (A: May. 2025 )
=16.008--85.189
=101.20

CytoDyn's Total Liabilities for the quarter that ended in Feb. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=42.662+(23.011+38.202
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=103.88

Total Liabilities=Total Assets (Q: Feb. 2026 )-Total Equity (Q: Feb. 2026 )
=15.648--88.227
=103.88

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of €103.88 Mil mean?
CytoDyn (STU:296) has a Total Liabilities of €103.88 Mil as of Feb. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for CytoDyn and its competitors.
Is CytoDyn's Total Liabilities too high?
CytoDyn's current Total Liabilities is €103.88 Mil. Overall, CytoDyn has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does CytoDyn's Total Liabilities compare to VSTM and IRD?
CytoDyn's Total Liabilities of €103.88 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for CytoDyn and its competitors. CytoDyn's current Total Liabilities is €103.88 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CytoDyn stock overvalued right now?
CytoDyn (STU:296) has a current Total Liabilities of €103.88 Mil. The current Total Liabilities is €103.88 Mil. CytoDyn's overall GF Score™ is 28/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For CytoDyn (STU:296), the current Total Liabilities is €103.88 Mil as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CytoDyn Business Description

Other Exchanges CYDY:USA
Address 1111 Main Street, Suite 660, Vancouver, WA, USA, 98660
CytoDyn Inc is a USA-based clinical-stage biotechnology company that focuses on the clinical development and potential commercialization of humanized monoclonal antibodies to treat Human Immunodeficiency Virus (HIV) infection. The product candidate is PRO 140, which is a class of HIV therapy called entry inhibitors that block HIV from entering into and infecting certain cells. The company emphasizes exploring opportunities for clinical applications for PRO 140 involving the CCR5 (C-C chemokine receptor type 5) receptor, other than HIV-related treatments, such as inflammatory conditions, autoimmune diseases, and cancer.
28GF Score

Get the complete analysis for STU:296

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.20
Price